Bluesky Facebook Reddit Email

TB vaccination could be overall cost-effective in 73 of 105 LMICs (70%) and produce economic benefits of US $474 billion by 2050, per modelling study by researchers at Harvard, LSHTM, the WHO and IAVI

01.24.23 | PLOS

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
TB vaccination could be overall cost-effective in 73 of 105 LMICs (70%) and produce economic benefits of US $474 billion by 2050, per modelling study by researchers at Harvard, LSHTM, the WHO and IAVI
Incremental net monetary benefit of novel tuberculosis vaccines assessed from the societal perspective, for several willingness-to-pay thresholds. Note: Estimates include the iNMB from the countries that are cost-effective at the respective threshold. GDP per capita estimates from 2020. GDP, gross domestic product per capita; iNMB, incremental net monetary benefit. Credit: Portnoy A, et al., 2023, PLOS Medicine, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)

In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine : http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004155

Article Title: The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

Author Countries : United States, United Kingdom, Netherlands, Switzerland, China

Funding: see manuscript

PLOS Medicine

10.1371/journal.pmed.1004155

Computational simulation/modeling

Not applicable

Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Members of the funder (NG, MZ, SYS, RH, IGB, NN) participated as authors on the study and critically reviewed the analysis, reviewed and revised the manuscript, and approved the final manuscript as submitted. All other authors have declared that no competing interests exist.

Keywords

Cost Effectiveness Economics Research Tuberculosis Vaccination Vaccine Research

Article Information

Journal
PLOS Medicine
DOI
10.1371/journal.pmed.1004155
Method of Research
Computational simulation/modeling
Subject of Research
Not applicable
COI Statement
Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Members of the funder (NG, MZ, SYS, RH, IGB, NN) participated as authors on the study and critically reviewed the analysis, reviewed and revised the manuscript, and approved the final manuscript as submitted. All other authors have declared that no competing interests exist.

Contact Information

Claire Turner
PLOS
medicinepress@plos.org

How to Cite This Article

APA:
PLOS. (2023, January 24). TB vaccination could be overall cost-effective in 73 of 105 LMICs (70%) and produce economic benefits of US $474 billion by 2050, per modelling study by researchers at Harvard, LSHTM, the WHO and IAVI. Brightsurf News. https://www.brightsurf.com/news/1ZZ5MNR1/tb-vaccination-could-be-overall-cost-effective-in-73-of-105-lmics-70-and-produce-economic-benefits-of-us-474-billion-by-2050-per-modelling-study-by-researchers-at-harvard-lshtm-the-who-and-iavi.html
MLA:
"TB vaccination could be overall cost-effective in 73 of 105 LMICs (70%) and produce economic benefits of US $474 billion by 2050, per modelling study by researchers at Harvard, LSHTM, the WHO and IAVI." Brightsurf News, Jan. 24 2023, https://www.brightsurf.com/news/1ZZ5MNR1/tb-vaccination-could-be-overall-cost-effective-in-73-of-105-lmics-70-and-produce-economic-benefits-of-us-474-billion-by-2050-per-modelling-study-by-researchers-at-harvard-lshtm-the-who-and-iavi.html.